Alimera Sciences (NASDAQ:ALIM) Coverage Initiated by Analysts at began coverage on shares of Alimera Sciences (NASDAQ:ALIMGet Rating) in a report issued on Monday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright raised their price target on Alimera Sciences from $8.00 to $9.00 and gave the stock a buy rating in a research report on Thursday, July 28th.

Alimera Sciences Stock Down 0.4 %

ALIM opened at $4.19 on Monday. Alimera Sciences has a 52 week low of $3.94 and a 52 week high of $7.92. The business has a fifty day simple moving average of $5.21 and a 200-day simple moving average of $5.64. The firm has a market cap of $29.34 million, a P/E ratio of -1.59 and a beta of 1.38.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Alimera Sciences stock. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Alimera Sciences, Inc. (NASDAQ:ALIMGet Rating) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 250,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,400,000. Healthcare of Ontario Pension Plan Trust Fund owned 3.58% of Alimera Sciences at the end of the most recent quarter. 34.53% of the stock is owned by institutional investors and hedge funds.

Alimera Sciences Company Profile

(Get Rating)

Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.

Featured Articles

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with's FREE daily email newsletter.